MDElliottMD: home-claude category backfill (parser-claude gap closure)

2026-05-23T10:43:36Z

home-claude category backfill (parser-claude gap closure)

← Older revision		Revision as of 10:43, 23 May 2026
Line 21:		Line 21:
	== References ==		== References ==
	<references />		<references />
			[[Category:Calcium channel blockers]]
			[[Category:Antianginals]]
			[[Category:Antiarrhythmics]]
			[[Category:Antihypertensives]]

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #177

2026-05-23T03:56:07Z

parser-claude batch MedTemplate pre-fill, Top 300 #177

New page

{{MedTemplate
| generic = Verapamil
| brand = Calan, Calan SR, Verelan, Verelan PM, Isoptin SR
| structure =
| classes = [[:Category:Calcium_channel_blockers|Calcium channel blocker (non-dihydropyridine)]], [[:Category:Antianginals|Antianginal]], [[:Category:Antiarrhythmics|Antiarrhythmic (class IV)]], [[:Category:Antihypertensives|Antihypertensive]]
| uses = <vote slug="hypertension-use">Hypertension</vote>, <vote slug="stable-angina-use">Stable and vasospastic angina</vote>, <vote slug="afib-rate-control-use">Atrial fibrillation/flutter rate control</vote>, <vote slug="psvt-use">Paroxysmal SVT (acute IV)</vote>, <vote slug="cluster-headache-prophylaxis-use">Cluster headache prophylaxis (high-dose, off-label)</vote>
| starting_dose = IR 80-120 mg PO TID; ER 180-240 mg PO daily; IV 2.5-5 mg over 2 min for SVT termination (under monitoring); cluster prophylaxis up to 480-960 mg/d in divided doses
| preparations = IR 40, 80, 120 mg tablets; SR/ER 100-360 mg; IV 2.5 mg/mL
| fda_max = ~480 mg/d (oral) for cardiovascular indications; higher off-label for cluster
| pill_id =
| routes = Oral (IR and multiple ER), IV
| onset = IV: 1-3 minutes (SVT termination); PO IR: 30-60 minutes; ER: hours
| duration = IR: 6-8 hours; ER: 24 hours
| halflife = 3-7 hours (IR); functional 24 hours (ER)<ref name="calan-label">FDA Prescribing Information, Calan (verapamil HCl), Pfizer/Pharmacia, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018817s033lbl.pdf</ref>
| bioavailability = ~20-35% (oral; extensive first-pass via CYP3A4 with R/S enantiomer differences)<ref name="calan-label" />
| pregnancy = Limited data; alternative antihypertensives generally preferred. Crosses placenta.{{citation needed}}
| legal = [[USLegal:Prescription only|Rx-only]] in US
| mechanism = <vote slug="verapamil-mech-claim">Verapamil is a phenylalkylamine non-dihydropyridine calcium channel blocker with the most pronounced AV nodal and cardiac myocyte L-type channel blockade in the class; it slows AV conduction, suppresses SVT, and reduces myocardial contractility, with modest peripheral vasodilation.</vote> Avoid in HFrEF (negative inotropy) and Wolff-Parkinson-White with AF (can accelerate antegrade accessory-pathway conduction). CYP3A4 substrate AND strong inhibitor — clinically dangerous interactions with simvastatin (max 10 mg), tacrolimus, cyclosporine, and many other CYP3A4 substrates<ref name="calan-label" />. Constipation is the dose-limiting non-cardiac adverse effect.
}}

== References ==
<references />

Verapamil - Revision history

MDElliottMD: home-claude category backfill (parser-claude gap closure)

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #177